Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REaCT-OGF: Omission of G-CSF in Breast Cancer
NCT05753618Phase 4Recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Apr 2023
- Primary completion
- Oct 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 4 trial of filgrastim in breast cancer, sponsored by Ottawa Hospital Research Institute. Started Apr 2023; status: recruiting.
02
Drugs
filgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05753618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753618.